SOHO Brazil 2024

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

SOHO Brazil 2024

Videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

By SOHO Brazil 2024 FEATURING Jeffrey Lancet

142 views

July 11, 2024

Comments 0

Videos

SOHO Brazil 2024: Treatment of Primary CNS Lymphoma

SOHO Brazil 2024

A. Alencar

117 views

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

215 views

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

531 views

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

913 views

Managing Infectious Complications With Bispecific and CAR-T Therapy …

SOHO Brazil 2024

N. S. Raje

202 views

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

430 views

Frontline MM: Are Four Better Than Three?

SOHO Brazil 2024

N. S. Raje

84 views

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

504 views

To 2L and Beyond: Treatment Options in R/R MCL

SOHO Brazil 2024

T. Phillips

39 views

FL Updates: Is There a Standard 1L Treatment?

SOHO Brazil 2024

B. Kahl

327 views

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

559 views

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

397 views

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

598 views

Are We Closer to Conquering HR-MDS?

SOHO Brazil 2024

R. Komrokji

111 views

Therapies on the Horizon in LR- and HR-MDS

SOHO Brazil 2024

R. Komrokji

159 views

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

SOHO Brazil 2024

A. Zelenetz

61 views

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

SOHO Brazil 2024

A. Zelenetz

127 views

Summary of Updates in R/R DLBCL Treatment

SOHO Brazil 2024

A. Alencar

110 views

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

613 views

Summary of Recent Updates in R/R HL

SOHO Brazil 2024

C. Moskowitz

130 views

Summary of Recent Updates on LR-MDS Management

SOHO Brazil 2024

R. Komrokji

47 views

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

SOHO Brazil 2024

J. Burger

128 views

Early Stage HL: Can Radiation Therapy Be Eliminated?

SOHO Brazil 2024

C. Moskowitz

115 views

PNH: Summary of Latest Advancements and Case Discussion

SOHO Brazil 2024

B. Fattizzo

252 views

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

SOHO Brazil 2024

J. Lancet

142 views

Making Sense of 1L Treatment Options in MCL

SOHO Brazil 2024

T. Phillips

125 views